Nasdaq · Biotech stocks database
CLLS — Cellectis S.A. ☆
CLLS (Cellectis S.A.) stock: $1.07, $107.6M market cap, $61.5M cash, $46.1M EV, $130.2M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
We were incorporated as a société anonyme, or S.A., under the laws of the French Republic on January 4, 2000 for a period of 99 years. We are registered at the Paris Registre du Commerce et des Sociétés under the number 428 859 052. Our principal executive offices are located at 8, rue de la Croix Jarry, 75013 Paris, France, and our telephone number is +33 1 81 69 16 00.
Source: 20-F FY2025 via SEC EDGAR
Balance sheet
Cash $61.5M Debt $0.0M Net cash $61.5M Enterprise value $46.1M Basic shares 100.5M shares Fully diluted shares 121.7M shares Fully diluted market cap $130.2M Cash per share $0.61 Quarterly burn $6.0M Cash runway 10.3 quarters
Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2025-12-31.
Price history Loading CLLS daily closes…
Loading price history…
Next catalyst eti-cel · Est. Nov 15, 2026 · quarter midpoint · guided Now All upcoming catalysts (+1 more) →
Upcoming catalysts Expected Drug Phase Indication Mgmt guide GUIDED Est. Nov 15, 2026 Now quarter midpoint
eti-celNATHALI-01 Phase 1 (full dataset) · NCT05607420
Phase 1 Not disclosed Q4 2026 GUIDED Est. Nov 15, 2026 Now quarter midpoint
lasme-celBALLI-01 pivotal Phase 2 trial (first interim analysis) · NCT04150497
Phase 2 Not disclosed Q4 2026
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Asset data not yet available for this company.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.